Linagliptin Krka

Linagliptin, the active ingredient in Linagliptin Krka, is a DPP-4 inhibitor presented as an oral tablet for oral use. It belongs to the antidiabetic therapeutic class and is marketed in the European Union for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.

GNH USA supplies Linagliptin Krka as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU GMP standards and provides reliable logistics for global distribution.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): reduces fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin or other oral agents. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports overall blood‑sugar management alongside lifestyle measures.

Linagliptin may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient head discomfort of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: occasional light‑headed sensation. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: rare skin blistering disorder. - Severe hypoglycaemia: when combined with insulin or sulfonylureas.

When prescribing Linagliptin, clinicians should consider the following precautions.

- Renal impairment: monitor renal function; dose adjustment is generally not required but caution is advised. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: observe for any worsening of heart conditions. - Pregnancy: safety not established; avoid unless clearly needed. - Breastfeeding: unknown safety; weigh benefits against potential risks. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Rifampin (strong enzyme inducer): may lower Linagliptin plasma concentrations and reduce efficacy. - Strong P-glycoprotein inhibitors (e.g., ketoconazole): may increase Linagliptin exposure and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia; monitor blood glucose. - Diuretics: may affect renal handling of glucose and alter glycaemic control. - NSAIDs: potential impact on renal function, especially in patients with existing kidney disease.